311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I

A Phase 1b 2a study of budoprutug in patients with immune thrombocytopenia ITP

Early loss of platelet response and rehospitalization following high dose dexamethasone in patients with newly diagnosed ITP

Teriflunomide an oral dihydroorotate dehydrogenase inhibitor in immune thrombocytopenia

Complement activation profile in primary immune thrombocytopenia Its association with PA IgM increased platelet turnover and clinical outcomes

All trans retinoic acid for refractory cancer therapy induced thrombocytopenia A new option beyond TPO ras

Clinical characteristics treatment strategies and response patterns in evans syndrome Initial analysis from the spanish resti cohort

Outcomes of septic shock in immune thrombocytopenia

Outcomes of immune thrombocytopenia hospitalizations in patients with diabetes mellitus

Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent chronic immune thrombocytopenia in the long term extension period of the Phase 3 LUNA3 study

Thrombotic risk with thrombopoietin receptor agonists in immune thrombocytopenia Real world evidence from a multicenter Japanese study

Comparative efficacy and safety of FcRn inhibitors versus placebo in adult immune thrombocytopenia A systematic review and meta analysis of randomized controlled trials

Immature platelet fraction as a marker for romiplostim discontinuation in immune thrombocytopenia Experience from cuenca Ecuador

Hetrombopag for the treatment of chemotherapy induced thrombocytopenia in advanced solid tumors A multicenter randomized double blind placebo controlled phase III trial

Real world safety and efficacy of avatrombopag in adults with immune thrombocytopenia A systematic review and meta analysis

Improved health related quality of life HRQoL and bleeding scores with oral bruton tyrosine kinase BTK inhibitor rilzabrutinib in the open label OL period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia ITP

Switching ITP patients to avatrombopag from other TPO ras A real world experience of the spanish ITP group GEPTI

Comparative risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag versus romiplostim A target trial emulation in the french adult immune thrombocytopenia FAITH cohort